Gaynor E R, Fisher R I
Division of Hematology/Oncology, Loyola University Medical Center, Maywood, Illinois, USA.
Oncology (Williston Park). 1995 Dec;9(12):1273-9; discussion 1283-4.
While it would seem obvious that dose intensity is an important determinant of treatment outcome in aggressive lymphomas, actually there are very few prospective data to support this hypothesis. Circumstantial evidence derived from retrospective analyses suggests that dose intensity is of clinical significance. However, based on available phase II and III data and the one prospective randomized trial to date that has specifically addressed this issue, it remains unclear what impact dose intensity has on treatment outcome.
虽然剂量强度似乎显然是侵袭性淋巴瘤治疗结果的一个重要决定因素，但实际上几乎没有前瞻性数据支持这一假设。回顾性分析得出的间接证据表明剂量强度具有临床意义。然而，根据现有的II期和III期数据以及迄今为止专门针对这一问题的一项前瞻性随机试验，目前尚不清楚剂量强度对治疗结果有何影响。
